Hi, your search found this article for you on Trip:

A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension

NHS Economic Evaluation Database., 2000

A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension
Health technology The use of two long-acting dihydropyridine calcium antagonists, amlodipine and nisoldipine extended-release, for the treatment of mild to moderate hypertension.
Hypothesis/study question The objective of the study was to compare the economic and clinical implications of using amlodipine versus nisoldipine in patients with mild to moderate hypertension.
Study population The study population comprised adult patients with Stage I or II hypertension, as defined by diastolic blood pressure (DBP) criteria of the Sixth Report of the Joint National Committee.
Patients were excluded if they had any known form of secondary hypertension, a systolic blood pressure (SBP) of greater than 200 mmHg or a DBP of greater than 110 mmHg, or bradycardia (heart rate less than 45 beats per minute, bpm) or tachycardia (heart rate greater than 100 bpm).
Other criteria for exclusion were congestive heart failure (left ventricular ejection fraction less than 40%), clinically significant hepatic or renal disease, uncontrolled diabetes mellitus, and a history of allergy or intolerance to the study medications.
Dates to which data relate The dates during which the effectiveness and resource use data were gathered were not reported.
Link between effectiveness and cost data The costing was performed prospectively on the same sample of patients as that used in the effectiveness study.
However, the study sample comprised 146 patients because 15 were excluded due to treatment noncompliance, refusal to continue, or noncompletion of the trial due to adverse events.
The mean age was 52.9 ( 14.6) years in the nisoldipine group and 56.3 ( 10.1) years in the amlodipine group.
Study design This was a prospective, randomised, double-blind, double-dummy parallel-group trial that was carried out in 9 centres.